Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a
Open Access
- 1 June 1996
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 39 (6) , 1006-1015
- https://doi.org/10.1002/art.1780390618
Abstract
Objective. To evaluate the ability of low‐dose cyclosporin A (CsA) to control radiologic disease progression, and to assess the clinical efficacy and tolerability of CsA, compared with conventional disease‐modifying antirheumatic drugs (DMARDs), in patients with early active rheumatoid arthritis (RA). Methods. In this long‐term, multicenter, prospective, open, blinded end point, randomized trial, 361 consenting patients with early (< 4 years since diagnosis) active RA were enrolled. Of the eligible patients, 167 were treated with CsA at 3 mg/kg/day, and 173 with DMARDs. The decision to use conventional antirheumatic drugs as controls was based on the fact that joint erosion could be expected to occur after 1 year regardless of the type of DMARD being used. The possibility of switching therapies in both groups was intended to keep the largest possible number of patients in the study. Results. Blinded evaluation of hand and foot radiographs after 12 months of treatment showed that CsA led to a significant (P < 0.001) delay in the mean ± SD progression in the eroded joint count (1.3 ± 3.1 versus 2.4 ± 3.0 for the control group) and in the joint damage score (3.6 ± 8.9 versus 6.9 ± 9.1 for the control group), both measured by the Larsen‐Dale method. When only the patients without erosion at baseline were considered (37 in the CsA‐treated group and 54 in the control group), erosion appeared in only 10.8% of the CsA‐treated patients, but in 51.8% of the controls (P = 0.00005). Low‐dose CsA was as effective as traditional DMARDs in controlling clinical symptoms. Maintenance on the initially prescribed treatment regimen (“survival on treatment”) was also better at 12 months with CsA than with DMARDs (89.2% versus 77.5%; P = 0.002). The tolerability of CsA was acceptable. Conclusion. These 12‐month results suggest that low‐dose CsA decreases the rate of further joint damage in previously involved joints as well as the rate of new joint involvement in previously uninvolved joints, in patients with early RA.Keywords
This publication has 35 references indexed in Scilit:
- A randomized, double‐blind, 24‐week controlled study of low‐dose cyclosporine versus chloroquine for early rheumatoid arthritisArthritis & Rheumatism, 1994
- Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?Annals of the Rheumatic Diseases, 1993
- Cyclosporin in the treatment of rheumatoid arthritisJournal of Autoimmunity, 1992
- Biannual Radiographic Assessments of Hands and Feet in a Three‐Year Prospective Followup of Patients with Early Rheumatoid ArthritisArthritis & Rheumatism, 1992
- Immunotherapy of rheumatic diseases - practice and prospectsImmunology Today, 1991
- The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty‐five years of diseaseArthritis & Rheumatism, 1991
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Does Drug Therapy Slow Radiographic Deterioration in Rheumatoid Arthritis?New England Journal of Medicine, 1983
- Controlled multicenter trial of tiopronin and D‐penicillamine for rheumatoid arthritisArthritis & Rheumatism, 1982
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976